Medical Condition News

RSS

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

CPIC awarded $2.6M grant to examine obesity, cancer risk within California Teachers Study

The National Cancer Institute has awarded a $2.6 million grant to the Cancer Prevention Institute of California. The award, which is part of a larger collaborative grant, supports CPIC's study of body size and cancer risk within the California Teachers Study, one of the largest longitudinal studies of women's health.

22 Oct 2010

Experts agree on key policy recommendations for management, prevention of rheumatic, MSKD

On 19 October 2010, experts from academia, scientific societies, patient organisations, Member States' government and social security institutions as well as EU bodies agreed upon a number of key policy recommendations for improving the management and prevention of rheumatic and musculoskeletal diseases.

22 Oct 2010

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Six research projects on co-existing heath problems associated with mental illness and one project on palliative care among First Nations received over $9 million in funding announced today. This amount is provided by the Canadian Institutes of Health Research and the Rx&D Health Research Foundation.

22 Oct 2010

Researchers suggest gene therapy may treat patients with major depression

In a report published in the Oct. 20 issue of Science Translational Medicine, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say animal and human data suggest gene therapy to the brain may be able to treat patients with major depression who do not respond to traditional drug treatment.

22 Oct 2010

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.

22 Oct 2010

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

An exciting new study conducted by Children's Hospital Oakland Research Institute scientists identified that an injection of the protein apolipoprotein A-V may reduce high triglyceride levels in the blood and subsequently reduce coronary artery disease. Like cholesterol, elevated levels of triglyceride, a fat in the blood, is associated with the increased risk of heart disease—the number one cause of death in the United States.

22 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Atherotech to present VAP Cholesterol Test at OMED 2010

Atherotech Diagnostics Lab will showcase its VAP Cholesterol Test in booth 324 at the American Osteopathic Association's 115th Annual Osteopathic Medical Conference & Exposition (OMED 2010). The gathering of DOs, residents, interns, students, researchers and health care professionals will be held October 24-28 at Moscone Convention Center in San Francisco.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

Snoring may destroy grey matter

A new Australian study has found that snoring and troubled nights could be a warning of brain damage occurring while sleeping. The team looked at brain scans of 60 people, aged in their mid-40s and recently diagnosed with a common sleep disorder – obstructive sleep apnea. Obstructive sleep apnea often affects overweight and the obese and leads to snoring. Results showed “decreased amount of grey matter” when compared to healthy sleepers.

21 Oct 2010

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

21 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

IDEV includes two stents to SUPERA product line for treating patients with peripheral vascular disease

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line.

21 Oct 2010

Cerenis raises €10 million in second close of Series C financing

Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.

21 Oct 2010

Medical Condition News

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

CPIC awarded $2.6M grant to examine obesity, cancer risk within California Teachers Study

Experts agree on key policy recommendations for management, prevention of rheumatic, MSKD

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Researchers suggest gene therapy may treat patients with major depression

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Atherotech to present VAP Cholesterol Test at OMED 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Snoring may destroy grey matter

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

IDEV includes two stents to SUPERA product line for treating patients with peripheral vascular disease

Cerenis raises €10 million in second close of Series C financing

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News